financetom
Business
financetom
/
Business
/
Homebuilder Hovnanian Enterprises Q3 revenue rises 10.8% on strong home sales growth
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Homebuilder Hovnanian Enterprises Q3 revenue rises 10.8% on strong home sales growth
Aug 21, 2025 6:58 AM

Overview

* Hovnanian ( HOV ) Q3 fiscal revenue rises 10.8% to $800.6 mln, meeting estimates

* Net income for fiscal Q3 falls to $16.6 mln from $72.9 mln a year ago

* 86% of total lots are optioned, highest percentage ever achieved

Outlook

* Company expects Q4 revenue between $750 mln and $850 mln

* Hovnanian ( HOV ) sees Q4 adjusted homebuilding gross margin at 15%-16.5%

* Company anticipates Q4 adjusted EBITDA between $77 mln and $87 mln

* Hovnanian ( HOV ) projects Q4 adjusted income before taxes of $45 mln-$55 mln

Result Drivers

* REVENUE INCREASE - Total revenues rose 10.8% to $800.6 mln in Q3, driven by a 9.3% increase in domestic unconsolidated joint ventures' home sales revenues to $165.0 mln

* GROSS MARGIN DECLINE - Homebuilding gross margin percentage, after cost of sales interest expense and land charges, decreased to 11.7% from 19.1% a year ago, with a noted increase in land charges from 0.1% to 2.1%

* CONTRACTS GROWTH - Consolidated contracts in Q3 increased 1.6% to 1,211 homes, while contracts including domestic unconsolidated joint ventures rose 1.4% to 1,416 homes

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $800.58 $801.20

Revenue mln mln (1

Analyst)

Q3 EPS $2.14

Q3 Net $16.62

Income mln

Q3 $23.80

Pretax mln

Profit

Analyst Coverage

* The one available analyst rating on the shares is "hold"

* The average consensus recommendation for the homebuilding peer group is "hold"

* Wall Street's median 12-month price target for Hovnanian Enterprises Inc ( HOV ) is $120.00, about 24.1% below its August 20 closing price of $148.95

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ross Stores Adds 40 New Locations
Ross Stores Adds 40 New Locations
Oct 13, 2025
09:13 AM EDT, 10/13/2025 (MT Newswires) -- Ross Stores ( ROST ) said Monday it recently opened 36 Ross Dress for Less and four dd's Discount across 17 different US states between September and October. The new store locations complete the company's fiscal 2025 growth plans, with the addition of 90 new store locations throughout the year, Ross Stores (...
NioCorp Developments Prices $150.2 Million Equity Offering
NioCorp Developments Prices $150.2 Million Equity Offering
Oct 13, 2025
09:13 AM EDT, 10/13/2025 (MT Newswires) -- NioCorp Developments ( NB ) said Monday it has priced a direct offering of up to about 16.1 million shares or pre-funded warrants at $9.34 per share, for gross proceeds of around $150.2 million. The offering is expected to close on Wednesday, the company said. NioCorp said it plans to use net proceeds...
American Battery Technology Completes Key Environmental Studies Requirement for Nevada Lithium Project
American Battery Technology Completes Key Environmental Studies Requirement for Nevada Lithium Project
Oct 13, 2025
09:15 AM EDT, 10/13/2025 (MT Newswires) -- American Battery Technology ( ABAT ) said Monday that it had completed and submitted all required baseline studies and subsequent reports to the US Bureau of Land Management as part of the National Environmental Policy Act review process. The company said the submission marks a milestone in the development of its Tonopah Flats...
Immutep Completes Dosage Optimization Requirements for Potential Lung Cancer Immunotherapy
Immutep Completes Dosage Optimization Requirements for Potential Lung Cancer Immunotherapy
Oct 13, 2025
09:08 AM EDT, 10/13/2025 (MT Newswires) -- Immutep ( IMMP ) said Monday it received positive and straightforward feedback from the US Food and Drug Administration regarding successful completion of Project Optimus dosing requirements and agreement on 30 milligrams as the best dosage for its cancer immunotherapy eftilagimod alfa. The agreement will help in future clinical development of the therapy,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved